Humanwell Healthcare (Group) Co.Ltd(600079) april 27 disclosed the annual report of 2021 and the first quarterly report of 2022. In 2021, the operating revenue will reach 20.441 billion yuan; The net profit attributable to shareholders of listed companies was 1.390 billion yuan, an increase of 20.99% over the same period of last year; The deduction of non net profit attributable to shareholders of listed companies was 1.078 billion yuan, an increase of 41.39% over the same period of last year.
In the first quarter of 2022, the company realized an operating revenue of 5.160 billion yuan, an increase of 10.48% over the same period of last year; The non net profit deducted attributable to shareholders of listed companies was 327 million yuan, an increase of 20.57% over the same period of last year.
The announcement shows that Humanwell Healthcare (Group) Co.Ltd(600079) since 2019, the revenue has exceeded 20 billion yuan, and the revenue has been more than 20 billion yuan for three consecutive years. The deduction of non net profit has increased continuously from 538 million yuan in 2019, 762 million yuan in 2020 and 1.078 billion yuan in 2021. The deduction of non net profit of the enterprise has increased by more than 40% for three consecutive years.
Humanwell Healthcare (Group) Co.Ltd(600079) relevant person in charge said that under multiple challenges such as repeated covid-19 pneumonia epidemic, Humanwell Healthcare (Group) Co.Ltd(600079) has always maintained steady and high-quality development, the company’s business quality is getting higher and higher, its profitability is continuously enhanced, and its core competitiveness is becoming more and more prominent.
refocusing focus anchor segment
On April 2, Humanwell Healthcare (Group) Co.Ltd(600079) announced the transfer of Tianfeng Securities Co.Ltd(601162) 785% of its equity to Hubei Hongtai Group Co., Ltd., with a total transfer price of about RMB 2.124 billion. This is the second major action in refocusing since 6 Qinghai Salt Lake Industry Co.Ltd(000792) 022.
As early as January, Humanwell Healthcare (Group) Co.Ltd(600079) sold the 24.57% equity of hande humanwell held by its wholly-owned subsidiary at the price of 174 million US dollars. This transaction will enable the company to realize an investment income of about 540 million yuan in 2022.
Insiders said that starting from the sale of Huatai Insurance shares in November 2021, Humanwell Healthcare (Group) Co.Ltd(600079) divestiture of financial assets has taken substantial steps. The equity transfer of Tianfeng Securities Co.Ltd(601162) is the second step of Humanwell Healthcare (Group) Co.Ltd(600079) stripping financial assets, which shows that Humanwell Healthcare (Group) Co.Ltd(600079) management is determined to focus on the strategy.
Previously, Li Jie, chairman of Humanwell Healthcare (Group) Co.Ltd(600079) group, told investors that Humanwell Healthcare (Group) Co.Ltd(600079) is determined to implement the refocusing strategy. The company will continue to promote refocusing and focus, gradually withdraw from the subdivided areas with less competitive advantage or weak synergy as planned, and concentrate resources to develop the subdivided areas with competitive advantage according to the idea of product line.
Under this idea, Humanwell Healthcare (Group) Co.Ltd(600079) while withdrawing from non core fields, it will strengthen the focus and investment in advantageous subdivided fields.
In October 2020, Humanwell Healthcare (Group) Co.Ltd(600079) increased its minority stake in Yichang humanwell through major asset restructuring, and further strengthened its control over its core subsidiaries to optimize and integrate the allocation of resources, concentrate resources on the development of established professional segments, realize business focus and asset optimization, and enhance the overall value of listed companies.
innovation strength breakthrough
In terms of R & D and innovation, in 2019, 2020 and 2021, the Humanwell Healthcare (Group) Co.Ltd(600079) R & D investment was 760 million yuan, 940 million yuan and 1.05 billion yuan respectively, accounting for more than 10% of the company’s pharmaceutical industry revenue, and the annual growth of R & D investment reached more than 10%.
The increase of R & D investment year by year makes Humanwell Healthcare (Group) Co.Ltd(600079) the new drug R & D full of stamina. In 2021, Humanwell Healthcare (Group) Co.Ltd(600079) Group Pharmaceutical Research Institute set up 41 new projects and 9 innovative drugs in the clinical stage. In order to strengthen the construction of the group’s innovation capacity, Humanwell Healthcare (Group) Co.Ltd(600079) within the framework of the group’s Pharmaceutical Research Institute, a new innovative drug research institute was established to focus on innovative drugs and high-end generic drugs, enrich product reserves and cultivate long-term competitiveness.
In terms of conformity evaluation of generic drugs, by the end of 2021, Humanwell Healthcare (Group) Co.Ltd(600079) there were 37 varieties and a total of 58 products with product specifications had passed the conformity evaluation of generic drugs (including deemed passing), of which 7 products were the first evaluated varieties in China.
build the whole value chain capacity of global R & D, registration, production and sales
Humanwell Healthcare (Group) Co.Ltd(600079) relevant person in charge introduced that the international development of the company started in 2009, and it is a pharmaceutical enterprise with an earlier layout of international business in China. The development of internationalization has won market space for enterprises and improved their competitiveness.
In 2021, Humanwell Healthcare (Group) Co.Ltd(600079) made every effort to cope with the challenges of overseas epidemics, seized the market opportunities and adjusted the product structure. The sales revenue of American generic drug business increased significantly.
During the reporting period, the sales revenue of Humanwell Healthcare (Group) Co.Ltd(600079) US generic drug business exceeded RMB 1.5 billion, an increase of about 13% over the same period of last year; All subsidiaries accelerated the application of product development, and obtained the Anda number of oseltamivir phosphate capsule, venlafaxine hydrochloride sustained-release capsule, memantine hydrochloride sustained-release capsule, metoprolol succinate sustained-release tablets and other products during the reporting period.
Up to now, Humanwell Healthcare (Group) Co.Ltd(600079) has owned the first soft capsule drug manufacturer exported to the United States in Hubei Province and the first Hubei pharmaceutical preparation Enterprise certified by FDA in Hubei Province. The subsidiaries of the group have successively obtained more than 110 anda approval numbers, and Wuhan puke, Yichang Renfu, Gedian Renfu, three Gorges pharmaceutical and renfukang have successively passed the system certification of the United States and the European Union.
“During the 14th Five Year Plan period, the company will seize the double opportunities of its own internationalization process and national policies in line with international standards, comprehensively carry out drug import registration, Chinese conversion of foreign key products and simultaneous declaration of generic drugs between China and the United States, so as to realize the coordinated development of Humanwell Healthcare (Group) Co.Ltd(600079) ‘going out and bringing in’, and the double cycle development pattern of international market and Chinese market.” Humanwell Healthcare (Group) Co.Ltd(600079) relevant person in charge said.
